Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C19-IG 20% versus placebo in asymptomatic ambulatory adults with SARS-CoV-2 infection
2021-000269-34Phase 3Terminated
- Sponsor
- Grifols
- Start
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing C19-IG 20% with Placebo (2 arms). Primary endpoint: Proportion remaining asymptomatic through Day 14. Started Apr 2021; status: terminated.
02
Drugs
Anti-COVID-19 Immune Globulin (Human)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-000269-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000269-34.